Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Change in Receivables (2019 - 2025)

Zevra Therapeutics' Change in Receivables history spans 7 years, with the latest figure at $6.4 million for Q4 2025.

  • For Q4 2025, Change in Receivables rose 134.17% year-over-year to $6.4 million; the TTM value through Dec 2025 reached $12.0 million, up 274.39%, while the annual FY2025 figure was $12.0 million, 274.39% up from the prior year.
  • Change in Receivables reached $6.4 million in Q4 2025 per ZVRA's latest filing, up from -$1.4 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $8.7 million in Q1 2021 to a low of -$9.4 million in Q2 2021.
  • Average Change in Receivables over 5 years is $995400.0, with a median of $1.2 million recorded in 2022.
  • Peak YoY movement for Change in Receivables: tumbled 5376.74% in 2021, then soared 2436.26% in 2022.
  • A 5-year view of Change in Receivables shows it stood at -$91000.0 in 2021, then skyrocketed by 2436.26% to $2.1 million in 2022, then surged by 250.42% to $7.4 million in 2023, then plummeted by 63.5% to $2.7 million in 2024, then skyrocketed by 134.17% to $6.4 million in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Change in Receivables are $6.4 million (Q4 2025), -$1.4 million (Q3 2025), and $4.9 million (Q2 2025).